WEI-CHIH LIAOLin J.-T.Wu C.-Y.Huang S.-P.MING-TSAN LINWu A.S.-H.Huang Y.-J.MING-SHIANG WU2020-03-232020-03-2320081078-0432https://www.scopus.com/inward/record.uri?eid=2-s2.0-38949083209&doi=10.1158%2f1078-0432.CCR-07-1032&partnerID=40&md5=f9bd26d9235bca7a498b59caa3e1c154https://scholars.lib.ntu.edu.tw/handle/123456789/477478Purpose: It has been suggested that interleukin-6 (IL-6) is a prognostic indicator for survival in patients with gastric carcinoma, but this has not been proved using survival analysis. In Asians, the -634G allele is associated with increased IL-6 production. The objective of this study was to evaluate the association between serum IL-6 levels, -634G/C polymorphism, and overall survival after resection for gastric carcinoma. Experimental Design: A total of 155 consecutive patients with gastric carcinoma were evaluated. Serum IL-6 levels were analyzed using an enzyme-linked immunoabsorbent assay. Genotype was determined by PCR and restriction fragment length polymorphism. Serum levels and survival were correlated with genotype and clinicopathologic factors. Results: Age and stage, but not -634G/C genotype,were associated with serum IL-6 levels. The median survival for patients with stage II or stage III gastric carcinoma was 1,418 days in patients with low (?13 pg/mL) versus 618 days in patients with high (>13 pg/mL) serum IL-6 levels (P = 0.038). Results of a multivariate analysis showed that serum IL-6 level of >13 pg/mL was a significant predictor of poor survival (hazard ratio, 1.77; 95% confidence interval, 1.07-2.92; P = 0.026). Conclusions: Serum IL-6 level of >13 pg/mL correlates with tumor progression and is an independent predictor of poor survival after resection. In patients with stage II and III gastric carcinoma, serum IL-6 level is more effective than stage as a prognostic indicator. By measuring IL-6, these patients can be divided into two groups with significant differences in survival. The -634G/C polymorphismis not associated with serum IL-6 level or survival. ? 2008 American Association for Cancer Research.[SDGs]SDG3interleukin 6; adult; advanced cancer; aged; article; cancer surgery; cancer survival; early cancer; enzyme linked immunosorbent assay; female; genetic polymorphism; genotype; human; major clinical study; male; overall survival; polymerase chain reaction; prediction; priority journal; restriction fragment length polymorphism; stomach carcinoma; Aged; Disease Progression; Female; Genotype; Humans; Interleukin-6; Linear Models; Male; Middle Aged; Neoplasm Staging; Polymorphism, Genetic; Stomach Neoplasms; Survival Ratejournal article10.1158/1078-0432.CCR-07-1032181982212-s2.0-38949083209